RNA: From the mes­sen­ger to the med­i­cine

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to senior editors Kyle Blankenship and Amber Tong.

In the 1990s, my col­leagues and I were gene hunters. In the years be­fore the hu­man genome was ful­ly se­quenced, we searched tire­less­ly for the ge­net­ic roots of dis­ease. It was a decades-long en­deav­or to first de­fine a syn­drome, then lo­cate the re­spon­si­ble gene, de­ter­mine its se­quence, study its mu­ta­tions and ma­nip­u­late it for ther­a­peu­tic ben­e­fit.

At the time, RNA sci­ence wasn’t be­ing se­ri­ous­ly con­sid­ered. DNA was our star, and RNA was a bit play­er.

It’s a dif­fer­ent sto­ry to­day, now that mR­NA vac­cines that were de­vel­oped in record time are pro­tect­ing mil­lions of peo­ple from a dan­ger­ous ill­ness. There is a dawn­ing aware­ness of the po­ten­tial for RNA-based med­i­cines. The CEO of the Bill & Melin­da Gates Med­ical Re­search In­sti­tute, Pen­ny Heaton, calls mR­NA vac­cines the be­gin­ning of “a new gold­en age of vac­ci­nol­o­gy.”

But she could have been even more op­ti­mistic. Be­cause af­ter decades of re­search in­to this nu­cle­ic acid that was once seen as a hum­ble as­sis­tant to DNA, RNA sci­ence is of­fer­ing new in­sights in­to in­tractable con­di­tions whose caus­es were pre­vi­ous­ly a mys­tery. It’s al­so un­lock­ing pow­er­ful new treat­ments.

Genes tell the body what to do. But if their code is gar­bled or in­com­pre­hen­si­ble, dis­ease will get the up­per hand. RNA—present in every cell in the body—is the mes­sen­ger of these im­por­tant in­struc­tions. These mes­sages (RNA tran­scripts) can be edit­ed to achieve a sub­stan­tial ther­a­peu­tic ef­fect, and this has im­pli­ca­tions in a wide range of de­gen­er­a­tive dis­eases.

It’s hard to be­lieve we ever viewed RNA as a poor re­la­tion to DNA. It’s not just a gold­en age for vac­cines that we have en­tered, it’s the be­gin­ning of a whole new era for med­ical sci­ence.

The op­por­tu­ni­ty

Hun­dreds of dis­eases can be traced to dys­func­tion­al pro­teins in the body. While DNA es­sen­tial­ly in­structs cells to cre­ate or reg­u­late these pro­teins in a way that pro­motes health and sur­vival, there are of­ten mis­prints, ty­pos, dele­tions and oth­er er­rors in DNA’s in­struc­tions. Con­se­quent­ly, the body some­times fails to pro­duce nec­es­sary pro­teins, pro­duces tox­ic pro­teins or fails to prop­er­ly reg­u­late pro­tein pro­duc­tion. This means dis­ease.

It al­so means the po­ten­tial for RNA-based med­i­cines, which seek to cor­rect these er­rors, is vast. And these treat­ments of­fer some­thing that gene ther­a­py or gene edit­ing does not: the abil­i­ty to make changes to cells that are re­versible and will not last a life­time.

Un­like gene ther­a­pies or gene edit­ing, RNA can be made to func­tion the way con­ven­tion­al drugs do. It can achieve a ther­a­peu­tic re­sult with­out mak­ing a per­ma­nent change to the pa­tient’s cells. Gene ther­a­pies or gene edit­ing risk cre­at­ing off-tar­get ef­fects in neigh­bor­ing cells and or­gans, which can be­come per­ma­nent changes. By con­trast, the body can shed an RNA ther­a­py the way it can shed the ef­fects of a drug.

The abil­i­ty of RNA to clar­i­fy DNA in­struc­tions to pro­mote hu­man health, with­out per­ma­nent al­ter­ations to a per­son’s cells, is why the po­ten­tial for RNA-based med­i­cines goes far be­yond de­vel­op­ing the next gen­er­a­tion of vac­cines. Biotech com­pa­nies are ex­plor­ing the many pos­si­bil­i­ties to­day.

One suc­cess­ful com­mon ap­proach in­volves “knock­ing down” dys­func­tion­al pro­teins that can lead to dis­ease, for ex­am­ple de­gen­er­a­tive con­di­tions like amy­otroph­ic lat­er­al scle­ro­sis (ALS) or meta­bol­ic dis­or­ders. Biotech com­pa­nies have been mak­ing in­roads on these con­di­tions by edit­ing RNA in­struc­tions to elim­i­nate a “gain-of-func­tion” pro­tein. In these cas­es, weak­en­ing the pro­duc­tion of cer­tain tox­ic pro­teins lessens the dis­ease im­pact.

Oth­er com­pa­nies are aim­ing not to elim­i­nate pro­teins but sim­ply al­ter their pro­duc­tion by splic­ing the pre-mR­NA that pro­vides their in­struc­tion guide and di­rec­tions for reg­u­la­tion. This is the case at Sarep­ta, where I pre­vi­ous­ly served as CEO and chief med­ical of­fi­cer.

The com­pa­ny I lead now, Stoke Ther­a­peu­tics, is pi­o­neer­ing a whole dif­fer­ent RNA ap­proach. Stoke is fo­cused on hap­loin­suf­fi­cien­cies or dis­eases like Dravet syn­drome (a se­vere and pro­gres­sive ge­net­ic epilep­sy) and au­to­so­mal dom­i­nant op­tic at­ro­phy that are caused by “loss of func­tion” mu­ta­tions in one copy of a gene, which re­sult in in­suf­fi­cient pro­tein lev­els that are es­sen­tial to hu­man health. Rather than knock­ing down the dys­func­tion­al gene, as oth­er com­pa­nies seek to do, Stoke is de­sign­ing RNA-based med­i­cines to in­crease ex­pres­sion of the prop­er­ly func­tion­ing gene in the pair, “up-reg­u­lat­ing” its pro­tein pro­duc­tion and there­by com­pen­sat­ing for the non-func­tion­al copy of the gene. By se­lec­tive­ly restor­ing, or “stok­ing”, the pro­duc­tion of the nat­u­ral­ly oc­cur­ring pro­tein, Stoke’s TAN­GO (Tar­get­ed Aug­men­ta­tion of Nu­clear Gene Out­put) ap­proach has the po­ten­tial to ad­dress the un­der­ly­ing ge­net­ic cause of hap­loin­suf­fi­cient dis­eases.

RNA sci­ence is even carv­ing out a pres­ence in di­ag­nos­tics, with RNA analy­sis of liq­uid biop­sy for can­cer en­abling ear­li­er di­ag­no­sis.

Vac­cines did not ush­er in a whole new era of RNA-based med­i­cine. But they shined a light on this area, which has been de­vel­op­ing steadi­ly for two decades, and which is open­ing the door to a seem­ing­ly end­less ar­ray of ap­pli­ca­tions, dis­ease states and treat­ment path­ways that, once ex­plored, will al­ter how we un­der­stand and treat ge­net­ic dis­eases.

The need

Be­fore I took the helm at biotech­nol­o­gy com­pa­nies, I treat­ed pa­tients at the point of care. Most of my pa­tients were chil­dren with rare dis­eases.

I have seen what ge­net­ic dis­eases can do, and I know the frus­tra­tion that comes with talk­ing to par­ents about id­io­path­ic con­di­tions that de­grade their chil­dren’s qual­i­ty of life – or worse. Id­io­path­ic means we just can’t shed much light on the cause of dis­ease, even when its ef­fects are all too vis­i­ble. For a doc­tor, the frus­tra­tion that came with di­ag­no­sis and treat­ment of id­io­path­ic con­di­tions was too in­tense to de­scribe.

One of the great things about this new era of ge­net­ic med­i­cine we are liv­ing in is that we now know far more about the caus­es of dis­ease. Many con­di­tions are in­her­it­ed.

But too of­ten, un­der­stand­ing the cause has not led to a cure or even a less­en­ing of the con­di­tion. Gene ther­a­py and gene edit­ing have shown ini­tial promise, but we need ad­di­tion­al strate­gies if we are to trans­late ful­ly our in­creased un­der­stand­ing of dis­ease in­to pow­er­ful treat­ments.

RNA is the next leg of this ex­cit­ing jour­ney. As DNA’s tran­scriber and mes­sen­ger, its use in med­i­cine brings us clos­er to stop­ping dis­eases of all kinds right at their source.

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Biopharma’s resident antibody-drug conjugate expert Seagen has scored a clutch of oncology approvals in recent years, finding gold in what are known as “third-gen” ADCs. Now, another of their partnered conjugates is ready for prime time.

The FDA on Monday handed an accelerated approval to Seagen and Genmab’s Tivdak (tisotumab vedotin-tftv, or “TV”) in second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy, the companies said in a release.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

Dave Lennon, former president of Novartis Gene Therapies

Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

Regenxbio, a small licensor of gene therapy viral vectors spun out from the University of Pennsylvania, is now finding itself in the middle of some major league patent fights.

In addition to a patent suit with Sarepta Therapeutics from last September, Novartis, is now trying to push its smaller partner out of the way. The Swiss biopharma licensed Regenxbio’s AAV9 vector for its $2.1 million spinal muscular atrophy therapy Zolgensma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Volker Wagner (L) and Jeff Legos

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

Ten years ago, a small Norwegian biotech by the name of Algeta showed up at ESMO — then the European Multidisciplinary Cancer Conference 2011 — and declared that its Bayer-partnered targeted radionuclide therapy, radium-223 chloride, boosted the overall survival of castration-resistant prostate cancer patients with symptomatic bone metastases.

In a Phase III study dubbed ALSYMPCA, patients who were treated with radium-223 chloride lived a median of 14 months compared to 11.2 months. The FDA would stamp an approval on it based on those data two years later, after Bayer snapped up Algeta and christened the drug Xofigo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Rafaèle Tordjman (Jeito Capital)

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

For a first-time fund, Jeito Capital talks a lot about continuity.

Rafaèle Tordjman had spotlighted that concept ever since she started building the firm in 2018, promising to go the extra mile(s) with biotech entrepreneurs while pushing them to reach patients faster.

Coincidentally, the lack of continuity was one of the sore spots listed in a report about the European healthcare sector published that same year by the European Investment Bank — whose fund is one of the LPs, alongside the American pension fund Teacher Retirement System of Texas and Singapore’s Temasek, to help Jeito close its first fund at $630 million (€534 million). As previously reported, Sanofi had chimed in €50 million, marking its first investment in a French life sciences fund.

Mi­rati tri­umphs again in KRAS-mu­tat­ed lung can­cer with a close­ly watched FDA fil­ing now in the cards

After a busy weekend at #ESMO21, which included a big readout for its KRAS drug adagrasib in colon cancer, Mirati Therapeutics is ready to keep the pressure on competitor Amgen with lung cancer data that will undergird an upcoming filing.

In topline results from a Phase II cohort of its KRYSTAL-1 study, adagrasib posted a response rate of 43% in second-line-or-later patients with metastatic non-small cell lung cancer containing a KRAS-G12C mutation, Mirati said Monday.

As­traZeneca, Dai­ichi Sanky­o's ADC En­her­tu blows away Roche's Kad­cy­la in sec­ond-line ad­vanced breast can­cer

AstraZeneca and Japanese drugmaker Daiichi Sankyo think they’ve struck gold with their next-gen ADC drug Enhertu, which has shown some striking data in late-stage breast cancer trials and early solid tumor tests. Getting into earlier patients is now the goal, starting with Enhertu’s complete walkover of a Roche drug in second-line breast cancer revealed Saturday.

Enhertu cut the risk of disease progression or death by a whopping 72% (p=<0.0001) compared with Roche’s ADC Kadcyla in second-line unresectable and/or metastatic HER2-positive breast cancer patients who had previously undergone treatment with a Herceptin-chemo combo, according to interim data from the Phase III DESTINY-Breast03 head-to-head study presented at this weekend’s #ESMO21.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.